Brenetafusp + Nivolumab + Nivolumab + Relatlimab
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Melanoma
Conditions
Advanced Melanoma
Trial Timeline
Jun 5, 2024 → Oct 16, 2027
NCT ID
NCT06112314About Brenetafusp + Nivolumab + Nivolumab + Relatlimab
Brenetafusp + Nivolumab + Nivolumab + Relatlimab is a phase 3 stage product being developed by Immunocore for Advanced Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06112314. Target conditions include Advanced Melanoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Melanoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06112314 | Phase 3 | Recruiting |
Competing Products
20 competing products in Advanced Melanoma